Strategic Financial Concepts LLC Buys New Position in Mesoblast Limited (NASDAQ:MESO)

Strategic Financial Concepts LLC purchased a new position in shares of Mesoblast Limited (NASDAQ:MESO) during the fourth quarter, Holdings Channel.com reports. The fund purchased 138,600 shares of the company’s stock, valued at approximately $2,744,000.

A number of other institutional investors also recently made changes to their positions in the stock. XY Capital Ltd bought a new position in Mesoblast during the third quarter valued at about $244,000. Jane Street Group LLC lifted its holdings in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after acquiring an additional 26,959 shares during the last quarter. Creative Planning bought a new position in shares of Mesoblast during the 3rd quarter valued at about $147,000. Clayton Financial Group LLC acquired a new position in shares of Mesoblast in the 4th quarter worth approximately $275,000. Finally, Ballentine Partners LLC bought a new stake in shares of Mesoblast in the 4th quarter worth approximately $222,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a report on Friday. Cantor Fitzgerald upgraded Mesoblast to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Stock Performance

Shares of MESO opened at $19.49 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. Mesoblast Limited has a 12 month low of $1.75 and a 12 month high of $22.00. The company’s fifty day moving average is $16.48 and its 200-day moving average is $11.04.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.